Mirati raises $101M; Can-Fite gains fast track status;

@FierceBiotech: Aerie skyrockets on a mixed success in second PhIII glaucoma study. Article | Follow @FierceBiotech

@JohnCFierce: First on Fierce: OrbiMed sets its sights on a $950M blockbuster biotech fund. News | Follow @JohnCFierce

> San Diego-based Mirati Therapeutics ($MRTX) raised $101 million in a new stock offering. Release

> The FDA has granted fast track status to Can-Fite's liver cancer drug. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Pentax backs $8M+ round for electrosurgery startup Creo. Article | Follow @FierceMedDev

@EmilyWFierce: Report: Cancer drug spending fuels large increases in Medicare discount drug program. ICYMI from FiercePharma | Follow @EmilyWFierce

> Mobile health apps top 165K mark, with 300 clinical trials using them. More

> Zoll buys an Israeli wearable cardiac monitor maker for $35M. Article

> FDA beefs up testing for duodenoscope cleaning devices. Report

Pharma News

@FiercePharma: ViroVet spins out of Aratana with focus on livestock health. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: BMS' Opdivo guns for kidney cancer nod with FDA 'breakthrough' tag. Article | Follow @CarlyHFierce

> BMJ: New analysis shows increased suicide rates in teens taking GSK's Paxil. More

> Celgene's Abraxane takes another hit from cost-effectiveness gatekeepers. Story

> Newly vocal union targets Big Pharma's payments to AHA and its leaders. Article

Vaccines News

> Takeda joins consortium that accelerates R&D for malaria, TB vaccines. Item

> Vaxent and PREVENT kick off Strep A vaccine trials. More

> Emory team to look at GSK vax response as part of NIH research. Report

> FDA panel recommends Fluad, possibly the first U.S. boosted flu jab. Story

> J&J's Janssen strikes four-year, $28.5M government partnership to advance Ebola vaccine. Article

CRO News

> PRA adding 150 jobs amid Pennsylvania expansion push. Report

> Chiltern closes its Theorem buy, doubling its workforce. Item

> Accelovance inks a nonprofit partnership for melanoma trials. Article

> WuXi brings its genomic heft to Chinese patients with hospital pact. Story

> Evotec upsizes its 2015 projections after a string of partnering deals. Article

Pharma Manufacturing News

> Pfizer Chinese JV partner Zhejiang Hisun Pharma gets FDA warning letter. More

> Nexvet picks up biologics plant in Ireland. Item

> FDA castigates Indian drugmaker over mess at API plant. Report

> Hamburg's pick in line to take over as FDA commissioner. Story

> FDA sears maker of GolfersSkin Sunscreen in warning letter. Article

Pharma Asia News

> Taiwan's TWi Pharmaceuticals raises $87M via GDR in weak pricing. Report

> China's Yabao Pharmaceutical adds to a summer string of tie-ups. Item

> Dual-listed Benitec adds fourth site for hep C trials of TT-034. More

> Low-cost genomic sequencing on the slate for China with Veritas landing? Story

> India's Glenmark says breast cancer candidate GBR 1302 moving to PhI. Article

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.